ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 163

Anti-Dense Fine Speckled (DFS) Autoantibodies in Autoinflammatory Vasculopathies

Asa Laestadius1, May Choi 1, Marvin Fritzler 1, Aurore Fifi-Mah 2, Susanne Benseler 3 and Joao Dantas 1, 1University of Calgary, Calgary, Canada, 2Calgary, Canada, 3Univeristy of Calgary, Calagry, Canada

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: autoantibodies, Biomarkers, systemic vasculitides

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Saturday, May 2, 2020

Title: Poster Session 3

Session Type: ACR Abstract Session

Session Time: 4:15PM-5:15PM

Background/Purpose: Autoantibodies to dense fine speckles 70 (DFS70) is now recognized to be more common among apparently healthy individuals compared to patients with ANA-related rheumatic disease (AARD). DFS70 autoantibodies has also been associated with milder rheumatic autoimmune disease  and has a higher prevalence in young women implicating age-related hormonal alteration. Whether anti-DFS70 is a clinically relevant biomarker in autoinflammatory vasculopathies (AV) not well studied. The objective of this study was to determine the frequency of anti-DFS70 in a spectrum of AV’s and whether anti-DFS70 has a clinically relevant correlation to patient demographic and clinical characteristics.

Methods: Patients diagnosed with AV by a rheumatologist (AF-M) in Calgary, Alberta, were enrolled in the Southern Alberta Vasculitis Patient Registry. Antibodies to proteinase 3 (PR3), myeloperoxidase (MPO), and DFS70 were detected by a chemiluminescence immunoassay. The association between anti-DFS70, diagnosis, age, sex, disease activity as assessed by Birmingham Vasculitis Activity Score (BVAS) and disease duration was described.

Results: There were 146 AV patients, 7 (4.8%) of which had a positive anti-DFS70 antibody. This included 1/22 (4.5%) giant cell arteritis, 2/35 (5.7%) granulomatosis with polyangiitis, 1/10 (10.0%) Behçet disease, 1/7 (14.3%) microscopic polyangiitis, 1/1 (100%) eosinophilic granulomatosis with polyangiitis, 1/6 (16.7%) IgA vasculitis. The mean age of patients with positive anti-DFS70 antibody was 57 years (standard deviation 46-83) with 57% being younger than 55-years-old. All patients were female. Sampling from diagnosis of disease ranged between 0-10 years, and BVAS was 0 in 6/7 patients and 2 in one patient.

Conclusion: The prevalence of anti-DFS70 autoantibodies in AV was rare (5%), similar to the frequency seen in other AARDs. Although the number of DFS70 positive patients were few, all patients were female with low disease activity.


Disclosure: A. Laestadius, None; M. Choi, None; M. Fritzler, Inova Diagnostics Inc., 1; A. Fifi-Mah, None; S. Benseler, None; J. Dantas, None.

To cite this abstract in AMA style:

Laestadius A, Choi M, Fritzler M, Fifi-Mah A, Benseler S, Dantas J. Anti-Dense Fine Speckled (DFS) Autoantibodies in Autoinflammatory Vasculopathies [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/anti-dense-fine-speckled-dfs-autoantibodies-in-autoinflammatory-vasculopathies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-dense-fine-speckled-dfs-autoantibodies-in-autoinflammatory-vasculopathies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology